Short sentence: Treatment of early-stage lung cancer requires multidisciplinary cooperation and close interaction between respiratory physicians, medical oncologists, radiation oncologists and thoracic surgeons.
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as potential important treatment modalities. To determine management for each patient, a thorough knowledge is required of the natural history of disease, risk assessment of the individual patient, evaluation of the diagnostic and staging examinations available, multidisciplinary input into individualised treatment plans, and importantly, discussion of the risks and benefits of treatment options with the patient. To this end every patient with presumed or proven lung cancer should be discussed within a dedicated multidisciplinary team (MDT) to ensure the optimal individualized therapeutic plan.
In this article, as part of the "Multidisciplinary questions in thoracic oncology", the different treatment modalities that are currently available for these patients are discussed in depth. The local modalities, surgery and RT, and their integration with systemic treatment are reviewed. Every co-author searched the literature over the past 10 years in his specific discipline. Main databases used were PubMed, Cochrane database and Web of Science. References of the selected papers and abstracts of major meetings were also screened for new, relevant data. As a broad area is covered, this manuscript cannot be considered a systematic review stricto sensu but a clear update is provided on management of stage I and II NSCLC.
When applicable, levels of evidence are mentioned (table 1) . Presently there are a number of grey areas, highlighting the need for further clinical research to provide high-level evidence for future recommendations.
DIAGNOSIS, PATIENT SELECTION AND STAGING

CT screening
The incidence of early stage NSCLC is expected to increase due to wider availability of CT scans and the introduction of screening in high-risk populations (1) . This will increase surgical workload. The higher risks of surgical morbidity and mortality in patients with multiple co-morbidities, coupled with an aging population suggests non-surgical management of early stage NSCLC is likely also to rise (2) .
Implication of changes in World Health Organisation (WHO) pathological classification
The new WHO classification of lung tumours, published in 2015, integrates immunohistochemistry in the classification of resected lung cancers (3) . A complete histological evaluation of the tumor is necessary for diagnosis and is of prognostic value. In this edition the American Thoracic Society (ATS)/ European Respiratory Society (ERS)/ International Association for the Study of Lung Cancer (IASLC) classification of adenocarcinoma published in 2011 was included without changes (4) . New subcategories include adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA). Complete histologic review should be performed to look for invasive foci with measurement of invasion. The term bronchioloalveolar carcinoma (BAC) which gave rise to much confusion, is not used anymore. Subtypes of invasive adenocarcinoma should be listed with their relative percentage indicated. This classification also has profound surgical implications which will be discussed further (5) .
Implication of changes in 8 th edition of TNM classification
In 2017, the 8 th TNM classification of lung cancer will be introduced (6, 7 TNM classifications are given in tables 2A and 2B, respectively, for comparison (6) (7) (8) .
Cardiopulmonary risk assessment
All patients should be discussed in a MDT to decide which treatment option is most suitable on an individual basis. Although there is no clear definition of high-risk patients, it should be kept in mind that empiric selection of patients may deny optimal oncologic management (9) . Even with modern computed tomographic (CT) and positron emission tomographic (PET) staging, pathologic upstaging is seen in up to 30% of patients (10, 11) . Multiple guidelines exist on selecting patients who are fit for surgery (12) (13) (14) (15, 19) .
The extent of resection and precise surgical approach are the subject of discussion. Additionally, with the advances in newer ablative techniques their role in early stage disease is currently debated, especially in medically compromised patients. In this section the indications for sublobar resections (SLR), sleeve resections and MIT approaches by video-assisted and robotic-assisted techniques (VATS/RATS) are discussed.
Conservative interventions: sublobar resection (SLR) and bronchoplastic procedures
Lobectomy has remained the standard of care for resection of early stage NSCLC since the prospective randomised Lung Cancer Study Group trial, comparing lobectomy with SLR (anatomical segmentectomy or wedge resection) for stage I NSCLC, which was published in 1995 (20) . The limited resection group had a three-fold increased incidence in local recurrence (p=0.008), a 30% increase in overall death rate (p=0.08) and a 50% increase in cancer related death (p=0.09) compared to patients undergoing lobectomy [level B evidence]. It is important to note that the limited resection arm included anatomical segmentectomies as well as non-anatomical wedge resections and tumours until 3 cm were eligible.
Since this study, there has not been another prospective trial on this topic. Several single centre retrospective studies have been published with conflicting conclusions (21, 22) . Landreneau et al. SLR is a valid alternative to lobectomy in lung cancer patients who meet the following criteria: stage IA disease, tumours up to 2 cm diameter, peripheral tumour location and predominantly ground-glass (nonsolid) appearance on CT imaging [level of evidence C] (28) . Anatomical segmentectomy is preferred over wedge resection since the latter is associated with higher rates of locoregional recurrence in stage IA NSCLC (29, 30 Next to the above mentioned distal lung parenchyma saving procedures, proximal bronchoplastic interventions as sleeve resections may be the treatment of choice in early stage NSCLC with proximal bronchial involvement or positive N1 nodes around a lobar bronchus (33, 34) . In this way a pneumonectomy is avoided. Conservative resections are more often performed in carcinoids or in patients with impaired pulmonary reserve (35) .
Minimally invasive surgery
MIT like VATS or RATS have been widely implemented as standard treatment for early stage NSCLC. Both were observed when a MIT was used. There was no significant difference in nodal upstaging rates and 30day mortality rates between the two groups. Comparing the two MIT, there was no significant difference between VATS and RATS in regards to nodal upstaging, 30-day mortality, and 2-year survival rates.
It is important to consider the role of nodal dissection, for which precise criteria have been established, to accurately stage the extent of cancer spread pathologically (38) . Medbery et al. conducted a retrospective analysis on the same National Cancer Database and reported nodal upstaging was more frequent in patients treated with lobectomy by thoracotomy than by VATS (12.8% versus 10.3%; p<0.001) (39). This difference was non-significant in patient groups treated in academic research facilities (39) .
Differences in quality of life (QOL) measures following open compared to VATS anatomic resection were
assessed in a prospective study and were found to be similar in both patient groups [level of evidence C] (40) . In addition the patient-reported physical component summary and pain scores after thoracotomy and VATS were also similar in both groups during the first 12 months after surgery (40).
Radiotherapy (RT)
Introduction
In addition to the advances in surgery over recent years, there have been dramatic developments in RT for NSCLC patients. RT is established as an alternative curative treatment option for patients with early stage disease, particularly in patients who are considered medically inoperable due to co-morbidities. In this section we compare local ablative therapies for stage I NSCLC and discuss the role of RT in a multidisciplinary setting as adjuvant and definitive treatment for stage I and II NSCLC. (42) . DFS was similar in both groups however severe ≥ grade 3 toxicity was lower in the SBRT group (10% vs 44%). Despite small numbers the data suggest 'at least clinical equipoise between the two treatment modalities' [level of evidence C]. However, as discussed in several Letters to the Editor, it should be noted that mortality in the surgical arm was unacceptably high, that histology was not obtained in every case, and that direct comparison of locoregional control between surgery and RT is not possible (43) (44) (45) (46) (47) (48) (49) . Further interest lies in comparing SBRT to surgical resection (lobectomy or SLR) in patients considered 'high-risk' for surgery. There are ongoing studies, assessing randomisation in this setting, currently recruiting ( Table 5 ).
Comparison of local ablative treatments for stage I NSCLC
The use of radiofrequency ablation (RFA) might rival with SBRT or SLR in early stage NSCLC. One study has compared the selection criteria and short-term outcomes in 3 prospective clinical trials that used SBRT (Radiation Therapy Oncology Group [RTOG] trial 0236), SLR (ACOSOG trial Z4032) and RFA (ACOSOG trial Z4033). The overall 90-day mortality for SBRT, surgery, and RFA was 0%, 2.4%, and 2.0%, respectively (p=0.5) [level of evidence C] (50). The RFA trial included older patients with more impaired lung function.
Another study has assessed the outcomes of SLR, RFA and radiation treatment in 116 patients with histologically proven stage I NSCLC from a prospective database (51 Interpretation of data from both these studies is limited as baseline patient characteristics were not comparable and treatment was not randomly assigned. In particular in the second study the RT group included patients treated with both SBRT (57%) and conventionally fractionated RT (43%). The median tumour size was significantly larger in the RT group compared to the other two groups. A large prospective RCT is required to assess the benefits of RFA in comparison to SBRT and surgery.
Adjuvant radiotherapy (RT) in resected early stage NSCLC
A meta-analysis of data from 9 randomised trials of adjuvant RT after resection of stage I-III NSCLC revealed a significant absolute detriment of 7% increased mortality at 2 years with the addition of RT [level A evidence] (52) . Subgroup analyses suggested that the adverse effect was greatest for patients with stage I and II disease and therefore adjuvant RT is not recommended for completely resected early stage disease (15, 53) . treatment. An important relative contraindication to SBRT however is active interstitial lung disease with higher than expected reported cases of severe or fatal pneumonitis in retrospective series (72, 73) .
Up to 20% of patients treated with SBRT will relapse with distant metastases after treatment (74, 75) .
There is no proven role for adjuvant chemotherapy following SBRT particularly in patients with larger lesions (≥4 cm) that would be considered for adjuvant therapy following resection. A study in this patient population would be interesting. However, given the majority of these patients are considered medically inoperable, many may not be suitable candidates for platinum-based systemic therapy.
In summary, SBRT is the standard of care for medically inoperable patients with early stage peripheral NSCLC [15, 16] . As outlined in the section above, in comparison with surgery in operable patients, SBRT remains an alternative and offers at least clinical equipoise with surgery, especially in those considered 'high-risk' for surgery until further evidence is available comparing the two modalities. Prospective trial data are awaited to determine the optimal dose schedules, in particular for central lesions (15, 76) .
Definitive (chemo)radiotherapy for stage II NSCLC
For the relatively small proportion of patients with medically inoperable stage II NSCLC not suitable for SBRT, usually because of ipsilateral hilar nodal involvement, the standard of care is treatment with chemo-radiotherapy (CRT) using conventional fractionation and platinum based regimens (77) (78) (79) . The role of concomitant compared to sequential chemotherapy in this patient group is less clear. In the landmark meta-analysis of over 1200 patients with stage I-III disease concomitant CRT was associated with a 4.5% benefit in OS at 5 years compared to a sequential approach at the expense of a significant increase in acute oesophageal toxicity from 4% to 18% (80) . However, less than 3% of the patients There is likely to be adverse selection bias for these patients with stage II disease given they were considered medically inoperable.
In summary, patients with inoperable stage II disease should be treated with definitive RT and consideration of the addition of chemotherapy concomitantly or sequentially should be given based on fitness to tolerate treatment. Further studies are required to assess the benefits of CRT in this population specifically. Additionally the role of treatment dose intensification with isotoxic RT schedules (83), oncogene targeted systemic therapies, DNA damage repair and immune checkpoint inhibitors also need to be explored.
Salvage surgery after stereotactic radiotherapy
For recurrent or persistent NSCLC after SBRT salvage surgery is a valid therapeutic option when a complete resection is feasible and cardiopulmonary functional assessment shows no contra-indication for the anticipated resection. Although surgical salvage is a relatively new concept in thoracic surgery, recent
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In contrast to the previous sections (locoregional treatment), in this section systemic therapy is discussed.
Platinum-based chemotherapy, targeted agents, immunotherapy and anti-angiogenic agents as adjuvant therapies for resected early stage NSCLC are discussed.
Adjuvant platinum-based chemotherapy
The RCT's of adjuvant cisplatin-based chemotherapy versus observation in patients with resected stage I-III NSCLC demonstrate statistically significant benefit for the addition of systemic therapy [level A evidence] (84) (85) (86) (87) (88) . An overview of these trials is provided in table 6. A meta-analysis of pooled data (n=4584) revealed a 5.3% (OS) and 5.2% (DFS) improvement at 5 years with the addition of cisplatin-based chemotherapy (89) . However, a statistically significant interaction between disease stage and chemotherapy effect was observed. In stage IA a potential detrimental effect was found with the addition of chemotherapy. In stage IB a trend was seen favouring the addition of systemic therapy [level B evidence]. A subsequent study of adjuvant carboplatin/paclitaxel in patients with resected stage IB NSCLC demonstrated no OS benefit, however an unplanned retrospective subgroup analysis revealed a benefit for patients with tumours of ≥4 cm (90) . Therefore, the ESMO guidelines state that adjuvant chemotherapy can be considered for the latter (15) . As mentioned previously, in the forthcoming 8 th TNM edition, it is proposed to reclassify tumours ≥ 4 cm as T2b (6) and subsequently these are grouped as stage IIA instead of stage IB (7) . The meta-analysis showed a clear OS benefit for adjuvant chemotherapy and it is advised in all current guidelines. However, tools to optimally select patients who benefit from chemotherapy are warranted, especially since the updated survival analysis of the International Adjuvant Lung Cancer Trial (IALT)
showed that the survival benefit did not persist after 5 years of follow-up, mainly due to increased nonlung cancer mortality in patients treated with adjuvant chemotherapy [level B evidence] (101). The histological NSCLC subtype has not been shown to be a predictive factor of benefit from adjuvant chemotherapy and as yet, there is no fully validated biomarker to identify patient subgroups who may derive particular benefit (91) . The IALT biomarker group has studied predictive value of several biomarkers including excision repair cross-complementation group 1 (ERCC1) and P53. ERCC1 expression seemed to be a predictive marker for response to platinum-based chemotherapy, with only ERCC1 negative tumours benefitting from adjuvant chemotherapy (102) . Although the randomised adjuvant TASTE trial showed that a biology driven randomised adjuvant trial is feasible, the planned phase III trial was terminated due to inaccuracy of the ERCC immunohistochemical staining classification (103) . Until now, no potential predictive biomarker has been validated in a RCT and none can be used to select patients who benefit from adjuvant chemotherapy. Invasive components of the tumour (vascular, lymphatic or perineural invasion) are also of prognostic significance in early stage NSCLC. Although not evaluated in RCT's it is possible that resected early stage patients with adverse prognostic factors would benefit more from adjuvant treatment than those without. In a meta-analysis (22 studies, total of 25280 patients with resected stage I NSCLC), visceral pleural invasion (VPI) was associated with death (HR 
Adjuvant targeted agents
The effect of adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) was tested in the BR19 study [level B evidence] (110) . Unselected patients with completely resected stage IB-IIIA NSCLC were randomised between gefitinib or placebo for 2 years. This study was closed prematurely, however it showed no benefit for adjuvant gefitinib (110) . In addition, no benefit was shown in the subgroup with an activating EGFR mutation (n=15). With the proven efficacy of EGFR-TKI's in mutation positive advanced disease, the role of adjuvant erlotinib versus placebo has been explored in patients with completely resected EGFR expressing (immunohistochemistry) or EGFR amplified (fluorescence in situ hybrisation) stage IB to IIIA disease (111 Other interesting immunotherapy strategies currently being explored in several phase III RCT's are the use of checkpoint inhibitors. As these studies started enrolment in 2015 results are expected within a few
years. An overview of these studies is provided in table…
Adjuvant anti-angiogenic agents
As angiogenesis is one of the hallmarks of cancer and important for growth and metastatic potential of tumours, the addition of bevacizumab to platinum-based chemotherapy was tested in a phase III RCT (E1505, n=1501) and presented at World Lung Cancer Conference 2015 (114 Results were presented at the ASCO 2016 conference: no significant differences in DFS were found, which is different from the results in the abstract (115) .
In summary, international guidelines recommend the use of adjuvant platinum-containing chemotherapy in patients with completely resected stage II disease and consideration of its use in patients with resected stage IB disease with a primary tumour ≥4 cm. According to the proposed 8 th TNM edition these are all grouped in stage II (15, 53) . Age is not a selection criterion per se, but co-existence of severe comorbidity may lead to detrimental outcome. Currently no predictive biomarkers of clinical benefit are available and new treatment strategies such as EGFR-TKI's, angiogenesis inhibitors and immunomodulation have not yet resulted in improved outcome but additional trials are ongoing.
CONCLUSION: MULTIDISCIPLINARY INTEGRATION
Integration of the different treatment modalities in patients with early stage NSCLC remains quite a challenge for the practicing oncologist. For this reason a thorough discussion within a MDT is required to determine the optimal diagnostic and treatment schedule for each individual patient. Although not always easy to define in daily practice, cardiopulmonary risk assessment is important to decide on the specific treatment or combination of therapeutic modalities that will be administered. PS, age, comorbidities and patients' preferences need to be taken into account also. Compromised patients will have to be treated less aggressively.
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This review summarises the key evidence behind the multidisciplinary decision making for individual patients with early stage NSCLC (table 6) . It also highlights some of the grey areas where further research is needed and discusses ongoing clinical trials. Undoubtedly, further development of MIT and SBRT, newly introduced chemotherapeutic and targeted agents in combination with further advances in immunotherapy, will provide a broad spectrum of therapeutic modalities. It is important to maintain clinical equipoise in presenting options to patients and to enrol patients in clinical trials where possible in order to better define the optimal treatment and improve outcomes for future patients with this disease. 
